SIGYN THERAPEUTICS INC - SIGY STOCK NEWS

Welcome to our dedicated page for SIGYN THERAPEUTICS news (Ticker: SIGY), a resource for investors and traders seeking the latest updates and insights on SIGYN THERAPEUTICS stock.

Sigyn Therapeutics, Inc. (OTCQB: SIGY) is a development-stage medical technology company based in San Diego, California. The company is pioneering blood purification technologies to address pathogen-associated inflammatory disorders, which are not effectively treated by traditional drug therapies.

Sigyn's flagship product, Sigyn Therapy™, targets a range of severe medical conditions including endotoxemia, sepsis, community-acquired pneumonia, and infections by drug-resistant bacteria and viruses. The initial clinical focus is on end-stage renal disease (ESRD) patients suffering from endotoxemia, a prevalent condition linked to increased mortality.

Further broadening its innovative portfolio, Sigyn Therapeutics is also developing ImmunePrep™, ChemoPrep™, and ChemoPure™. ImmunePrep™ aims to improve the efficacy of immunotherapeutic antibodies, a market projected to grow exponentially. ChemoPrep™ is designed to enhance the delivery and reduce the toxicity of chemotherapy, addressing a crucial need as less than 5% of chemotherapy reaches the tumor site. ChemoPure™ further mitigates chemotherapy toxicity by extracting off-target drugs from the bloodstream post-treatment.

Despite its development-stage status, Sigyn has demonstrated promising in vitro results, reducing the prevalence of multiple pathogen and inflammatory targets in human blood plasma. The company has initiated steps to begin first-in-human studies and is in the process of finalizing study protocols for Sigyn Therapy™ in ESRD patients.

On the financial front, Sigyn reported a net loss of approximately $4.1 million for the year ending December 31, 2023, indicating its commitment to research and development. The company recently completed a 1-for-40 reverse stock split, a strategic move aimed at meeting Nasdaq listing requirements.

Sigyn Therapeutics continues to advance its mission, positioning itself as a leader in the medical technology field with a comprehensive pipeline aimed at improving patient outcomes and addressing unmet medical needs.

03/05/2024 09:00 AM

News

Sigyn Therapeutics™ to Present at Tomorrow’s Emerging Growth Conference

Rhea-AI Summary

Sigyn Therapeutics, Inc. announces CEO Jim Joyce's live presentation at the Emerging Growth Conference to update on Sigyn TherapyTM and new cancer treatment products. The presentation will focus on a novel blood purification technology for life-threatening conditions and products to enhance chemotherapy and immunotherapy benefits.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

02/21/2024 08:45 AM

News

Sigyn Therapeutics™ Announces Filing of 2023 Annual Report on SEC Form 10-K

Rhea-AI Summary

Sigyn Therapeutics, Inc. filed its Form 10-K annual report with the SEC for 2023, introduced new therapeutic candidates, and prepared for first-in-human clinical studies. The company reported a loss from operations of $2.5 million and a net loss of $4.1 million for 2023.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

02/01/2024 06:25 PM

News

Sigyn Therapeutics Completes Reverse Stock Split

Rhea-AI Summary

Sigyn Therapeutics, Inc. announced a 1-for-40 reverse stock split, with the common stock trading under the ticker symbol 'SIGYD' for 20 days and then reverting to 'SIGY' on February 29, 2024. The Company also reported 1,221,043 common shares issued and outstanding as of January 31, 2024.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1900%

Tags

01/30/2024 08:45 AM

News

Sigyn Therapeutics Announces Reverse Stock Split

Rhea-AI Summary

Sigyn Therapeutics, Inc. announced a 1-for-40 reverse split of its common stock to increase the market price per share and gain compliance with the minimum bid listing requirement of The Nasdaq Capital Market. The reverse split will affect all stockholders uniformly and will not alter any stockholder’s relative interest in the Company’s equity.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

16.28%

Tags

01/04/2024 08:00 AM

News

Sigyn Therapeutics Releases Letter to Shareholders

Rhea-AI Summary

Sigyn Therapeutics, Inc. (SIGY) announces release of shareholder letter by Chairman and CEO, Jim Joyce, detailing the company's development-stage medical technology and prospects for its therapies. The letter provides an update on proposed underwritten financing and discusses the development of Sigyn TherapyTM, ImmunePrepTM, ChemoPrepTM, and ChemoPureTM platforms.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

12/12/2023 08:30 AM

News

Sigyn Therapeutics Announces Appointment of Jerry DeCiccio as Chief Financial Officer

Rhea-AI Summary

Sigyn Therapeutics, Inc. (SIGY) appoints Jerry DeCiccio, CPA, MBA, as Chief Financial Officer, bringing over 40 years of financial industry experience to the Company. Mr. DeCiccio has held executive roles at publicly traded companies, including Intech Electromechanical, GTC Telecom, Incomnet Communications, and Cerebain Biotech Corp. He has also served in senior financial roles at Parker Hannifin Corp., Waste Management Inc., and Newport Corp. Mr. DeCiccio's appointment follows the tenure of Jeremy Farrell, who was previously appointed CFO in March of 2022. The company expresses its appreciation for Farrell's service and looks forward to focusing on the clinical advancement of Sigyn Therapy and unlocking the value of its therapeutic pipeline with Jerry DeCiccio on board.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-28.21%

Tags

11/14/2023 05:11 PM

News

Sigyn Therapeutics Reports Third Quarter 2023 Financial Results

Rhea-AI Summary

Sigyn Therapeutics, Inc. (OTCQB: SIGY) announces financial results for Q3 2023, highlighting plans for first-in-human studies of Sigyn TherapyTM and pipeline technologies to enhance cancer therapies. The Company aims to address end-stage renal disease (ESRD) patients with endotoxemia, with a focus on safety. Financially, Sigyn had a loss from operations of approximately $642,814, and a net loss of approximately $905,726 for the quarter.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

10/04/2023 08:30 AM

News

Sigyn Therapeutics™ Discloses PCT Patent Submission to Enhance Chemotherapy Delivery and Reduce Cancer Treatment Toxicity

Rhea-AI Summary

Sigyn Therapeutics submits a Patent Cooperation Treaty (PCT) application to enhance chemotherapy delivery and reduce toxicity. The company is developing ChemoPrepTM and ChemoPureTM technologies to increase tumor-site saturation of chemotherapy agents with reduced doses. This may improve treatment outcomes, alleviate supply chain issues, and enhance patient quality of life. No concrete business takes affecting stock price are mentioned.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

09/06/2023 08:00 AM

News

Sigyn Therapeutics to Present at Today’s Emerging Growth Conference and Tomorrow at the National Investment Bankers Association Conference

Rhea-AI Summary

Sigyn Therapeutics, Inc. announces online presentation at Emerging Growth Conference and in-person presentation at NIBA Conference.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

08/14/2023 04:30 PM

News

Sigyn Therapeutics Reports Second Quarter 2023 Financial Results

Rhea-AI Summary

Sigyn Therapeutics, Inc. (SIGY) announces financial results for Q2 2023, including a focus on first-in-human studies of Sigyn TherapyTM and the introduction of ImmunePrepTM, a platform designed to enhance the delivery of immunotherapeutic antibodies. The company reported a loss from operations of approximately $574,009 and a net loss of approximately $723,124 for the quarter.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

12%

Tags

FAQ

What is the current stock price of SIGYN THERAPEUTICS (SIGY)?

The current stock price of SIGYN THERAPEUTICS (SIGY) is $5.25 as of August 22, 2024.

What is the market cap of SIGYN THERAPEUTICS (SIGY)?

The market cap of SIGYN THERAPEUTICS (SIGY) is approximately 7.3M.

What is Sigyn Therapeutics' core business?

Sigyn Therapeutics specializes in developing blood purification technologies to treat pathogen-associated inflammatory disorders that are not effectively addressed by conventional drug therapies.

What are the key products developed by Sigyn Therapeutics?

Key products include Sigyn Therapy™ for inflammatory disorders, ImmunePrep™ for enhancing immunotherapeutic antibodies, ChemoPrep™ for optimizing chemotherapy delivery, and ChemoPure™ for reducing chemotherapy toxicity.

What conditions does Sigyn Therapy™ aim to treat?

Sigyn Therapy™ focuses on treating conditions such as endotoxemia, sepsis, community-acquired pneumonia, and infections caused by drug-resistant bacteria and viruses.

What is the status of Sigyn Therapeutics' clinical trials?

The company is preparing to initiate first-in-human studies of Sigyn Therapy™ in end-stage renal disease (ESRD) patients with endotoxemia.

How is Sigyn Therapeutics performing financially?

For the year ending December 31, 2023, Sigyn reported a net loss of approximately $4.1 million, reflecting its substantial investment in research and development.

What recent strategic financial move did Sigyn Therapeutics make?

Sigyn Therapeutics completed a 1-for-40 reverse stock split to meet Nasdaq listing requirements.

Where is Sigyn Therapeutics headquartered?

Sigyn Therapeutics is headquartered in San Diego, California.

What is the market potential for Sigyn Therapeutics' products?

The potential market for ImmunePrep™ alone is projected to reach $566.72 billion USD by 2032, indicating significant growth opportunities for Sigyn products.

How can investors access more information about Sigyn Therapeutics?

Investors can access detailed financial results and updates on the company's website at www.SigynTherapeutics.com and on the SEC's website at www.sec.gov.